Startups
Proceeds from the Series A will be used to further advance the company’s Kinetic Ensemble platform and accelerate its R&D pipeline.
Retro Biosciences announced on Twitter that it is launching with $180 million in funding. Not much is known about the company, except that it indicates it is focused on the “cellular drives of aging.”
Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.
Aerium Therapeutics has officially launched following a successful Series A funding round led by seed investor Omega Funds.
In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
Creyon Bio, a drug development company, has launched with more than $40 million in seed and Series A financing led by DCVC Bio and Lux Capital.
Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.
Flagship will pour in $75 million into Vesalius to support its beginnings, while Rondo raised $67 million to support the development of its preclinical pipeline.
PRESS RELEASES